Overview
Prokarium develops vaccines against a variety of infectious diseases, basing the immunotherapy on Engineering Biology.
Using engineered strains of attenuated bacteria offers a cost-effective solution for the production of oral vaccines and bypasses the need for expensive protein purification steps. Since Prokarium’s Salmonella platform has already been proven safe, the biotech is now expanding into broader indications, ranging from vaccines against infections with clostridium difficile or chlamydia to candidates targeting the Zika virus or the bacterium Yersinia pestis, which causes plague.
Prokarium is pioneering the field of microbial immunotherapy. Their pipeline is designed to unlock the next level of immuno-oncology by building on the most recent advances in cancer immunology. Prokarium’s lead program is focused on transforming the treatment paradigm in bladder cancer by orchestrating immune-driven, long-lasting antitumor effects.
SynbiCITE was also able to support Prokarium in obtaining funding to perform preclinical studies on its lead Chlamydia vaccine. In 2015 Prokarium applied and received funding from SynbiCITE’s Development of Prototype (DoP) Fund to co-fund its critical pre-clinical studies on its lead candidate. SynbiCITE contributed £377K to Prokarium and academic collaborator Prof Robin Shattock of Imperial College to complete the pre-clinical development of its innovative Chlamydia vaccine. In addition, SynbiCITE has been able to offer its central London business facilities to Prokarium for business and board meetings.
Prokarium recently announced a $30 Million Financing to Deliver Lead Program into Clinic and Build Novel Therapeutic Platform. This follows Prokarium’s announcement of partnering with Ginkgo Bioworks to leverage its world-class Foundry and extensive Codebase to develop a bactofection platform technology.
Our Support
SynbiCITE Support
- DoP Funding
- London Biofoundry Support
